Sutherland Unveils Insurance AI Hub to Break Industry’s ‘Pilot Trap’
13.10.2025 15:41:00 EEST | Business Wire | Press release
Sutherland, a global leader in business and digital transformation, today announced the launch of its Insurance AI Hub, an agentic AI ecosystem engineered to solve the scale, compliance, and ROI challenges insurers face in operationalizing AI.
Unlike generalized AI platforms retrofitted for insurance or siloed tools that rarely make it beyond the demo stage, Sutherland’s solution is trained on real insurance workflows, tuned for regulatory demands, and already being deployed by enterprises today.
Now with a comprehensive suite of specialized AI agents engineered for Life & Annuity, Group Benefits, Property & Casualty, and Specialty lines, the Insurance AI Hub lets insurers break free from proof-of-concept paralysis and finally scale AI with confidence.
Sutherland’s AI offerings come with important enterprise guardrails already in place, featuring a human-in-the-loop framework, audit trails, and model transparency built in. It provides a true “ecosystem” purpose-built for insurance—from the infrastructure and models selected to the tailored use cases.
The Insurance AI Hub is already delivering impact across the policy lifecycle:
- Agentic AI for Claims & Enrollment streamlines complex disability and life claims with human-in-the-loop precision—cutting cycle times by up to 30%, reducing leakage by 12%, and lifting claimant satisfaction by 10+%.
- Voice AI engages customers through natural, human-like conversations across claims, servicing, and sales—boosting contact center efficiency by 20%, improving conversion by up to 3%, and increasing NPS by 10+ points.
- Connected Underwriting empowers underwriters with AI-driven triage and appetite matching—delivering 30% efficiency gains, 16% higher win rates, and 3.7x growth in high-appetite business.
- Cognilink Document Intelligence transforms manual, document-heavy workflows into automated, insight-driven processes—cutting OPEX by 30%, improving indemnity by 1–1.5%, and reducing leakage by 10–12%.
“Insurers don’t need more AI pilots—they need outcomes,” said Banwari Agarwal, CEO of Insurance, Banking and Financial Services at Sutherland. “The Insurance AI Hub was built with insurance DNA from day one. It delivers scalable agentic automation that understands the industry’s complexities, integrates into fragmented IT environments, and provides measurable results—not just demos.”
At its core, the Insurance AI Hub uses a modular, plug-and-play architecture that allows each AI agent to operate autonomously or collaboratively across claims, underwriting, servicing, and renewals. This enables insurers to accelerate adoption while maintaining full transparency, bias controls, and compliance alignment with SOC 2, HIPAA, and NAIC regulations.
With most insurers having already contracted with hyperscalers and tested GenAI in narrow pilots, the industry now faces its biggest hurdle: trusting the tools to scale and provide measurable ROI. The Sutherland Insurance AI Hub was built to bridge that gap.
About Sutherland
Artificial Intelligence. Automation. Cloud Engineering. Advanced Analytics.
For Enterprises, these are key factors of success. For us, they’re our core expertise.
We work with global iconic brands. We bring them a unique value proposition through market-leading technologies and business process excellence. At the heart of it all is Digital Engineering – the foundation that powers rapid innovation and scalable business transformation.
We’ve created 363 unique and independent inventions, 250 of which are AI-based and rolled up under several patent grants in critical technologies. Leveraging our advanced products and platforms, we drive digital transformation at scale, optimize critical business operations, reinvent experiences, and pioneer new solutions, all provided through a seamless “as-a-service” model.
For each company, we provide new keys for their businesses, the people they work with, and the customers they serve. With proven strategies and agile execution, we don’t just enable change — we engineer digital outcomes.
Know more: www.sutherlandglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013128638/en/
Contacts
For further queries: mediarelations@sutherlandglobal.com
Know more: www.sutherlandglobal.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sutherlandg
lobal.com%2F&esheet=54337278&newsitemid=20251013128638&lan=en-US&anchor=www.suth
erlandglobal.com&index=4&md5=5f999be206af38a6a1dcf144e7e411e6
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom